Department of Molecular Biology and Graduate School of Biomedical Sciences, School of Osteopathic Medicine, Rowan University, Stratford, NJ 08084, USA.
New Industry Creation Hatchery Center, Tohoku University; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
Oral Oncol. 2018 Mar;78:126-136. doi: 10.1016/j.oraloncology.2018.01.011. Epub 2018 Feb 20.
Oral cancer has become one of the most aggressive types of cancer, killing 140,000 people worldwide every year. Current treatments for oral cancer include surgery and radiation therapies. These procedures can be very effective; however, they can also drastically decrease the quality of life for survivors. New chemotherapeutic treatments are needed to more effectively combat oral cancer. The transmembrane receptor podoplanin (PDPN) has emerged as a functionally relevant oral cancer biomarker and chemotherapeutic target. PDPN expression promotes tumor cell migration leading to oral cancer invasion and metastasis. Here, we describe the role of PDPN in oral squamous cell carcinoma progression, and how it may be exploited to prevent and treat oral cancer.
口腔癌已成为最具侵袭性的癌症之一，每年在全球导致 14 万人死亡。目前口腔癌的治疗方法包括手术和放射疗法。这些方法非常有效；然而，它们也会极大地降低幸存者的生活质量。需要新的化疗药物来更有效地治疗口腔癌。跨膜受体 podoplanin（PDPN）已成为一种具有功能相关性的口腔癌生物标志物和化疗靶点。PDPN 的表达促进肿瘤细胞迁移，导致口腔癌侵袭和转移。在这里，我们描述了 PDPN 在口腔鳞状细胞癌进展中的作用，以及如何利用它来预防和治疗口腔癌。
